Pharmacal Recalls MG217 Eczema Cream Lot Over Staph Contamination

Key Takeaways

• Pharmacal recalled one lot of MG217 eczema cream due to Staphylococcus aureus contamination.
• The affected lot is 1024088, expiration November 2026.
• Consumers should stop use and discard the product.

Pharmacal has issued a nationwide consumer-level recall of 1 lot of MG217 Multi-symptom Treatment Cream & Skin Protectant Eczema Cream, 6-oz tube, after the product was found to be contaminated with Staphylococcus aureus, according to a company announcement posted by the US Food and Drug Administration (FDA). 

The recalled product is a topical cream sold in 6-oz tubes with product code 5106 and UPC 012277051067. The affected lot is 1024088, with an expiration date of November 2026. Consumers can identify the product by locating the lot number on the crimped end of the tube. 

Use of the contaminated product could result in infections ranging from localized infections to severe or life-threatening adverse events. Patients with weakened immune systems or compromised skin, including wounds, burns, or skin disorders, may be at increased risk for serious infections, including skin and skin structure infections, infective endocarditis, bone and joint infections, bloodstream infections, sepsis, and septic shock. 

Pharmacal said it has not received reports of adverse events related to the recall. The product was distributed nationwide to wholesale, retail, including H-E-B, and internet distributors, including Amazon. Pharmacal is notifying distributors by emailed letter and arranging returns of recalled products. 

Consumers who have the recalled product should stop using it and discard it. Questions may be directed to Pharmacal at 800-558-6614 or aimho@pharmacalway.com, Monday through Friday, 8 AM to 5 PM Central time. Consumers who experienced problems that may be related to the product should contact a physician or other health care professional and may report adverse events or quality problems to FDA MedWatch.